A Solution for Coral Cuts

May 13th 2025

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Your daily dose of the clinical news you may have missed.

May 7th 2025

Tirzepatide Demonstrates Greater Weight Loss Than Semaglutide in Head-to-Head Study

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

Full results from the SURMOUNT-5 trial showed tirzepatide achieved 20.2% mean weight loss vs 13.7% with semaglutide in adults with obesity or overweight.

Linda Stein Gold, MD;Sydney Jennings

March 9th 2025

Genetic Risk Score Identifies Individuals Likely to Report Adverse Events from GLP-1 Mimetic Therapy

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Grace Halsey

Tirzepatide Associated with Improved HF Symptoms, Renal Function in People with Obesity, CKD: Daily Dose

The ability to predict which individuals will experience adverse events from GLP-1 therapy has great promise for more personalized treatment and improved clinical trial design.

FDA Clears STS101 Nasal Powder for Acute Treatment of Migraine: Daily Dose

Your daily dose of the clinical news you may have missed.

Related Content

May 13th 2025

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Your daily dose of the clinical news you may have missed.

May 7th 2025

Tirzepatide Demonstrates Greater Weight Loss Than Semaglutide in Head-to-Head Study

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

Full results from the SURMOUNT-5 trial showed tirzepatide achieved 20.2% mean weight loss vs 13.7% with semaglutide in adults with obesity or overweight.

Linda Stein Gold, MD;Sydney Jennings

March 9th 2025

Genetic Risk Score Identifies Individuals Likely to Report Adverse Events from GLP-1 Mimetic Therapy

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Grace Halsey

Tirzepatide Associated with Improved HF Symptoms, Renal Function in People with Obesity, CKD: Daily Dose

The ability to predict which individuals will experience adverse events from GLP-1 therapy has great promise for more personalized treatment and improved clinical trial design.